ReShape Lifesciences (RSLS) Stock Price, News, Quotes-Moomoo

$ReShape Lifesciences (RSLS.US)$
ReShape Lifesciences (RSLS) reported Q3 2024 financial results, showing revenue growth of 16.6% over Q2 2024 and 6.4% year-over-year to $2.3 million.
The company achieved a 40.6% reduction in operating expenses for the first nine months of 2024 compared to 2023.
Gross profit margin improved to 62.8% in Q3 2024.
The company entered into a merger agreement with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys for $5.16 million.
ReSha...

Trytosaveabit

Nov 14 15:08

News

$ReShape Lifesciences (RSLS.US)$ Reuters· just
ReShape Lifesciences: Entered Into Merger Agreement With Vyome Therapeutics & Asset Purchase Agreement With Biorad Medisys

Trytosaveabit

Nov 12 07:36

News

$ReShape Lifesciences (RSLS.US)$ Reuters
4 mins ago
ReShape Lifesciences® Receives Health Canada Approval for Its Next-Generation Lap-Band® 2.0 Flex

Jaguar8

Nov 12 07:32

NEWS

$ReShape Lifesciences (RSLS.US)$
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX
ReShape Lifesciences (Nasdaq: RSLS) has received Health Canada approval for its next-generation Lap-Band® 2.0 FLEX and Tubing Kit. The enhanced device features new Flex technology that acts as a relief valve, allowing larger food pieces to pass through more easily by temporarily relaxing before returning to its resting diameter. Like its predecessor, the device can...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

RSLS ReShape Lifesciences

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target